VRAXVirax Biolabs Group Ltd

Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune in Long COVID and Related Post-Acute Infection Syndromes Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune in Long COVID and Related Post-Acute Infection Syndromes PR Newswire LONDON, May 26, 2026 LONDON, May 26...

Virax Biolabs Group Limited shares rose 17.36% after hours following heavy intraday gains and disclosure of a new 4.99% hedge fund stake.read more...

US stocks lower as Nasdaq falls 200 points, Dow down 0.04% and S&P 500 down 0.37%. Energy shares up 1.8%, tech stocks down 1.6%. Brady Corp reports strong earnings. Sunshine Biopharma, Virax Biolabs...

Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones...

A volatile mix of scientific breakthroughs, aggressive expansion, fresh capital inflows, and compliance risks is defining the current small- and micro-cap landscape. $KBLB, $RMSG, $VRAX, $ALMU, $IMA, $RCT, $NTRA, $ALLO, $RECT, $FFAI

The market is sending a mixed but telling signal: innovation is accelerating, but only the most disciplined and well-positioned companies are keeping pace. Across AI, biotech, and micro-cap tech, recent developments highlight a widening divide between firms gaining validation and those fighting to maintain footing in public markets. $BFRG, $TGNT, $LTRN, $VRAX, $KIDZ, $HKIT

Shares of Virax Biolabs Group are soaring Tuesday after it secured several regulatory certifications paving the way for clinical validation.read more...

Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD...

Virax Biolabs Group Limited (VRAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).